These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25705993)

  • 1. Hepatitis C and HIV co-infection: closing the gaps.
    Graham CS
    JAMA; 2015 Mar 24-31; 313(12):1217-8. PubMed ID: 25705993
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
    Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
    BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hepatitis C genotype 1. Harvoni and Holkira Pak reimbursed?].
    Sabourin G
    Perspect Infirm; 2015; 12(5):60. PubMed ID: 26730433
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
    Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
    Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
    Hussar DA; Kavelak HL
    J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Höner zu Siederdissen C; Cornberg M
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2411-4. PubMed ID: 25390631
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
    Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
    Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
    JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 4-drug combination (Viekira Pak) for hepatitis C.
    Med Lett Drugs Ther; 2015 Feb; 57(1461):15-7. PubMed ID: 25629810
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of direct-acting antiviral agent failures.
    Buti M; Riveiro-Barciela M; Esteban R
    J Hepatol; 2015 Dec; 63(6):1511-22. PubMed ID: 26299621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-drug combination (Viekira Pak) for hepatitis C.
    JAMA; 2015 May; 313(18):1857-8. PubMed ID: 25965236
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
    Ferreira VL; Leonart LP; Tonin FS; Borba HHL; Pontarolo R
    Clin Drug Investig; 2018 May; 38(5):389-400. PubMed ID: 29435907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
    Gentile I; Buonomo AR; Zappulo E; Borgia G
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):763-73. PubMed ID: 24918116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High chance for cure].
    Recker K
    MMW Fortschr Med; 2015 Jul; 157(13):81. PubMed ID: 26206055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.